View Latest Medical and Pharma Bids and Tenders

Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products With The Active Ingredients Lamivudine, Tenofovir Disoproxil And Doravirine (J05Ar24) As Part Of A So-Called Open-House Model.

Open House Drug Discount Agreements Lamivudine, Tenofovir Disoproxil And Doravirine, Atc J05Ar24

Open House Drug Discount Agreements Lamivudine, Tenofovir Disoproxil And Doravirine, Atc J05Ar24

Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products With The Active Ingredients Lamivudine, Tenofovir Disoproxil And Doravirine (J05Ar24) As Part Of A So-Called Open-House Model.

Open House Original Discount Agreements 2023-29 - Dolutegravir/Lamivudine (Combination Of Active Ingredients)

Open House Original Discount Contracts 2023-28 - Doravirin, Lamivudine, Tenofovir

Open House Original Discount Agreements 2023-29 - Dolutegravir/Lamivudine (Combination Of Active Ingredients)

Open House Original Discount Agreements 2023-28 - Doravirine, Lamivudine, Tenofovir

Open House Original Discount Contracts 2023-28 - Doravirin, Lamivudine, Tenofovir

Purchase Of Antiretroviral Drugs. Parts 1-3